AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01797835 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: usual care
Description: Youth receive a brochure with information on AOD use.
Study NCT00197392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bactiseal TM EVD
Description: Standard of care implantation of external ventricular drainage catheter
Study NCT00197392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard EVD Catheter
Description: Standard of care EVD system other than Bactiseal.
Study NCT00815256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen Cross Linking with Riboflavin and UVA light
Description: The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
Study NCT03121430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting peripheral vascular stent system
Description: Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
Study NCT03121430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol Stent System
Description: Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
Study NCT00857792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regadenoson
Description: Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
Study NCT02838511 — intervention group
Intervention type: OTHER
Intervention: Modified Frailty Index (MFI)
Description: non-cardiac surgical patients will have frailty evaluated
Study NCT02838511 — intervention group
Intervention type: OTHER
Intervention: Hopkins Frailty Score (HFS)
Description: non-cardiac surgical patients will have frailty evaluated
Study NCT01544738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aponeurotic stimulation (the diacutaneous fibrolysis method)
Description: Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
Study NCT01544738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo stimulation
Description: Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
Study NCT01593033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil and Micronutrient Supplementation
Description: 0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months
Study NCT01593033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Supplement
Description: 1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
Study NCT01593033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
Study NCT04422119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-Foam dressing
Description: Application of a multi-layer foam dressing with Safetac in surgical wound
Study NCT04422119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Care of surgical wound with povidone-iodine and a gauze dressing with plaster.
Study NCT04064814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine 5mg
Description: Flunarizine 5mg once daily,orally for 12 weeks
Study NCT04064814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flunarizine 5mg
Description: Flunarizine 5mg once daily,orally for 12 weeks
Study NCT04064814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid 300mg
Description: Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
Study NCT04390321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLMcare
Description: Participants will undergo 20 sessions of computerized cognitive and physical training, during a 2 month period. Both components have a duration of 30 minutes and are consecutive, but their sequence is pseudo-randomized. All sessions are conducted under supervision. Cognitive training uses the greek adaptation of the BrainHQ software (Posit Science Corporation), utilizing audiovisual stimuli, and targets memory, attention, cognitive-processing speed, orientation and social skills. Physical training is based on the WebFitForAll protocol and uses the motion sensor device Kinect. It consists of warm-up, aerobic, flexibility, strength, balance and cool down exercises.
Study NCT02439749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ multi-electrode renal denervation system
Description: After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
Study NCT02439749 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
Study NCT03715998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: 1 or 2 capsules administered orally, twice daily
Study NCT03715998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firibastat
Description: 1 or 2 capsules administered orally, twice daily
Study NCT01019473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT01019473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03396666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemouv
Description: Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
Study NCT01227278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
Study NCT01227278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
Study NCT01131572 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylcysteine NAC
Description: N-acetylcysteine in the treatment of Bulimia Nervosa
Study NCT03095313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-NaF
Description: At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol \[Omnipaque™\]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves.
Study NCT00074737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cenersen
Description: cenersen with standard of care
Study NCT00074737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: standard of care for AML
Study NCT00074737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: standard of care Ara-C and High dose Ara-C
Study NCT00793494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probaclac
Description: Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
Study NCT00793494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo composition matodextrin, gelatin, ascorbic acid, soya
Study NCT00786279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol
Description: 15 gm ethanol daily for 6 months
Study NCT00786279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ethanol-free beverage
Description: 0 grams ethanol daily for 6 months.
Study NCT03801382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IntelliSpace Cognition (ISC)
Description: Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
Study NCT04449926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus of Calmette and Guerin (BCG)
Description: Prime and boost vaccination
Study NCT04216238 — intervention group
Intervention type: BEHAVIORAL
Intervention: quasi-experimental Pre-test/Post-test design
Description: surveys to document progress
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Describing a shameful experience using a self-compassionate prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a self-compassionate prompt
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving compassionate responses from confederates
Description: Following the participant's description of a shameful experience, two confederates will respond with compassionate responses
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Describing a shameful experience using a neutral prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Describing a shameful experience using a neutral prompt
Description: Participants will be instructed to describe a shameful experience to two confederates using a neutral (i.e., not self-compassionate) prompt
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving no response from confederates
Description: Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
Study NCT04600557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Receiving no response from confederates
Description: Following the participant's description of a shameful experience, two confederates will not be allowed to provide any verbal response
Study NCT02619175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Subjects Perturbation-Based Balance Training
Study NCT02619175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Subjects Weight Shifting and Gait training
Study NCT03940222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive Binocular Treatment
Description: The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
Study NCT04470297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon 8mg
Description: Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
Study NCT04470297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon 8mg
Description: Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days
Study NCT04231071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onlay Mesh group
Description: Primary suture repair with a small only mesh on the closed defect
Study NCT04231071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onlay Mesh group
Description: Primary suture repair with a small only mesh on the closed defect
Study NCT03368196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: An antibody drug conjugate
Study NCT02049411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
Study NCT02049411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: physiological solution
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
Study NCT02049411 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: physiological solution
Description: physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
Study NCT03179761 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza Vaccine
Description: Standard Dose Quadrivalent Influenza Vaccine given intramuscularly
Study NCT03179761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03179761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03179761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: High Dose Trivalent Influenza Vaccine given intramuscularly
Study NCT01595087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
Study NCT03940222 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patching Therapy
Description: Patching of the dominant eye with better best corrected visual acuity
Study NCT03013738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growing Pro-Social Program
Description: GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
Study NCT03013738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
Study NCT03013738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
Study NCT01767896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous (sc)
Study NCT01767896 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: approved egg-derived TIV
Description: subcutaneous (sc)
Study NCT00766519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: volume optimization
Description: Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~  + systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%
Study NCT00766519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard volume administration
Description: Fluid management:~* basal fluid administration = 5 ml/kg/h lactated Ringer's solution~* hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV
Study NCT02838043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probio'Stick
Description: A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
Study NCT04036890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% minocycline hydrochloride controlled-delivery system (MHS)
Description: The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
Study NCT04036890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: It is the same gel as MHS but without active ingredient minocycline hydrochloride.
Study NCT01475357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1: NPO by mouth pre-operative
Description: Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
Study NCT01475357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Fresh Breast Milk pre-operative
Description: Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
Study NCT00547482 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TANTALUS(TM) System
Description: All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation).
Study NCT00547482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TANTALUS(TM) System
Description: All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation).
Study NCT02819414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol drops
Description: 15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
Study NCT02819414 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.25 ml/kg/dose x 4/day of sterile water to be given for three days
Study NCT03017183 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound guided transbronchial needle aspiration
Study NCT03017183 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial forceps biopsy
Description: Conventional endobronchial forceps biopsy
Study NCT01460446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aviva Expert blood glucose meter
Study NCT01460446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aviva Nano blood glucose meter
Study NCT03157401 — intervention group
Intervention type: DRUG
Intervention: intravenous infusion group
Description: In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
Study NCT03157401 — intervention group
Intervention type: DRUG
Intervention: intra-articular injection group
Description: In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.